VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS
|
|
- Neil Carter
- 6 years ago
- Views:
Transcription
1 VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS NATIONAL CONFERENCE OF STATE LEGISLATURES SAN DIEGO, CA DECEMBER 10, 2017
2 TODAY, THERE IS A SIGNIFICANT FOCUS ON DRUG PRICING May 29, 2017 Drug Lobbyists Battle Cry Over Prices: Blame the Others 1 May 31, 2017 As Drug Prices Soar, Value-Based Pay Hits Pharmaceutical Industry 2 May 8, 2017 Express Scripts and some drug makers say they can work together to lower costs 3 Price Transparency Is Critical to Drug Pricing Solutions 4 July 11, 2017 July 12, 2017 Drug Prices Under Fire, in the States 5 U.S. prescription drug spending as high as $610 billion by May 3, 2017 Sources: 1. Lipton E, et al. Drug Lobbyists Battle Cry Over Prices: Blame the Others. The New York Times Accessed 7/26/ Japsen B. As Drug Prices Soar, Value-Based Pay Hits Pharmaceutical Industry. Forbes Accessed 7/26/ Silverman E. Express Scripts and some drug makers say they can work together to lower costs. Stat Plus Accessed 7/26/ Turner GM. Price Transparency Is Critical to Drug Pricing Solutions. Forbes drug-pricing-solutions/#748829bf204a. Accessed 7/26/ Grant C. Drug Prices Under Fire, in the States. Wall Street Journal Accessed 7/26/2017. Amgen 6. Berkrot Proprietary For B. U.S. prescription Discussion drug spending Purposes as Only high as $610 billion by 2021: report. Reuters Accessed 7/26/2017.
3 DRUG SPENDING IN PERSPECTIVE Need Focus on Rising Healthcare Costs Demographic Shifts Rising Burden of Disease 1 Rising patient cost-sharing 2 $972 billion spent on hospital care in $765B annual healthcare waste in $428B in pharmacy-related waste in $471B in Insurance Administrative Costs 6 $340B in low-value care 7 Recent Focus on Drug Spending Looking at increasing trend without examining benefits delivered Evaluating prices in absence of value delivered and negotiated prices Focus on 4% of healthcare spending on highcost biologics 8 Short-term budget pressures impacting longterm investments in health Issues with the Supply Chain Sources: 1. Bodenheimer T, et al. Health Affairs. 2009;28(1): American College of Physicians Addressing the Increasing Burden of Health Insurance Cost Sharing. American College of Physicians Position Paper. 3. Centers for Medicare and Medicaid Services. National health expenditure 2014 highlights Smith M, et al. Institute of Medicine of the National Academies Express Scripts. Drug Trend Report Jiwani A, et al. BMC Health Services Research. 3 Amgen Proprietary For Discussion Purposes Only 2014;14: Fendrick M. The Cost of Low-Value Care. Am J Manag Care IMS Institute for Healthcare Informatics. Medicines Use and Spending in the U.S.: A Review of 2015 and Outlook to morningconsult.com/wp-content/uploads/2016/04/ims-institute-us-drug-spending-2015.pdf. Accessed July 27, 2017.
4 PRESCRIPTION DRUG SPENDING ACCOUNTS FOR ~14% OF TOTAL HEALTHCARE SPENDING IN THE U.S. Physician & Clinical Services 20% Dental 4% Govt & Private Health Insurance Admin 8% Spending on prescription medicines is A SMALL SHARE OF TOTAL U.S. HEALTHCARE SPENDING PRESCRIPTION DRUGS 2 Brand Manufacturers 7% Generic Manufacturers 3% Supply Chain Entities** 4% TOTAL 14% U.S. Healthcare Spending Other * 13% Nursing Home, Home Health 8% *Supply chain entities include wholesalers, pharmacies, pharmacy benefit managers, and health care provider locations. Hospital Care 32% *Other includes expenditures for Other Professional Services, Nondurable Medical Products, Durable Medical Equipment, Govt Public Health Activity, Research, Structures, and Equipment. Sources: 1. CMS. National Health Expenditures 2015 Highlights Reports/NationalHealthExpendData/downloads/highlights.pdf. Accessed 7/20/ Vandervelde A, Blalock E; Berkeley Research Group. The pharmaceutical supply chain: gross drug expenditures realized by stakeholders. 4 Amgen Proprietary For Discussion Purposes Only FINAL.pdf. Published Accessed May 2017.
5 US SYSTEM REDUCES PRICE TRANSPARENCY AND PROVIDES DIFFERING INCENTIVES Who Pays for Care? Government (CMS/States/ DoD/VA) Employers Patients Commercial Health Plans Who Are the Intermediaries? Wholesalers Pharmacy Benefit Managers (PBMs) Specialty Pharmacy Group Purchasing Organizations Who Delivers Care? Hospitals Physicians Integrated Delivery Networks (IDNs) Managed Care Organizations Retail Pharmacies Home Health Nursing Homes CMS = Centers for Medicare & Medicaid Services; DoD = US Department of Defense ; VA = US Department of Veterans Affairs Source: Data on file, Amgen; [VBP Presentation; March 2017]. 5 Amgen Proprietary For Discussion Purposes Only
6 SHARE OF 2015 DRUG EXPENDITURES REALIZED BY MANUFACTURER AND NON-MANUFACTURER STAKEHOLDERS ~$470B Total Drug Expenditure* ~$148B Realized by Non-Manufacturers Generic 23% Non- Manufacturers 31% Retrospective Rebates & Fees $17B Pharmacy $20B Innovator 46% Health Plans & PBMs*** $64B Gov t Insurers** $41B *2015 estimate **Inclusive of statutory rebates and fees including ACA Excise fees, Medicaid rebates, Part D Coverage Gap, TRICARE & FSS discounts ***Inclusive of negotiated health plan and Pharmacy Benefit Manager (PBM) rebates and fees and patient cost sharing assistance Wholesaler & Group Purchasing Organization $3B Source: The Berkeley Research Group. The Pharmaceutical Supply Chain: Gross Drug Expenditures Realized by Stakeholders. January Accessed October 19, Amgen Proprietary For Discussion Purposes Only
7 THE COST OF INNOVATION 12 years at ~$2.6B ~90% of clinical trials fail It takes an average of 12 years 1 at an investment of almost $2.6 billion 2 to advance one potential new medicine from research concept to an FDA-approved treatment. As of 2015, one in every 10 drugs that enter clinical trials successfully make it to market, 3 leaving many multi-million investments on the drawing board. ~58% of Ph III drugs are submitted for approval This low success rate is concerning because 35% of all R&D spending is for Ph III development which account for 60% of all clinical trial costs 3 Sources: 1. Van Norman, G. Drugs, Devices, and the FDA: Part 1. JACC: Basic to Translational Science. 2016;1(3): DiMasi J, Gradowski H, Hansen R. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47: BIO. Clinical Development Success Rates Amgen Proprietary For Discussion Purposes Only %20BIO,%20Biomedtracker,%20Amplion% pdf. Accessed 10/3/17.
8 WHAT IS THE REAL COST DEBATE? Is the cure worth the cost? But What is the cost of not improving treatments? 8 Amgen Proprietary For Discussion Purposes Only
9 WE NEED TO ADDRESS THE RISING COST OF THE MOST SERIOUS DISEASES CARDIOVASCULAR DISEASE #1 KILLER in the U.S. with 1 DEATH EVERY 40 SECONDS 1 Estimated to cost the U.S. more than $900B by CANCER 2 nd LEADING CAUSE OF DEATH in the U.S. 2 Every 1% reduction in the long-term cancer-related death rate yields $500B for society 3 ALZHEIMER S DISEASE 5.5 MILLION AMERICANS IMPACTED 4 Projected to cost more than $1.1T by Sources: 1. Benjamin E, et al. Circulation. 2017;135:e1-e Centers for Disease Control and Prevention. Accessed July 17, Murphy KM, et al. J Political Econ. 2006;114(5): Alzheimer s Association Alzheimer s Disease Fact and Figures. Available at: Accessed July 28, Alzheimer's Association. Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars Amgen Proprietary For Discussion Purposes Only
10 MEDICINES ARE PART OF THE SOLUTION TO ADDRESS INCREASING HEALTHCARE SPENDING For every additional dollar spent on medicines for patients with congestive heart failure, high blood pressure, diabetes and high cholesterol $3-$10 ADHERENCE TO VASCULAR MEDICINES HEALTHCARE SPENDING Savings generated on ER visits and inpatient hospitalizations 1 ~$10 per hypertension patient ~$8 per congestive heart failure patient ~$7 per diabetes patient ~$3 per dyslipidemia patient Congressional Budget Office Includes Medical Cost Offsets Due to Prescription Drugs in Medicare 2 Sources: 1. Roebuck C, et al. Medication Adherence Leads to Lower Health Care Use And Costs Despite Increased Drug Spending. Health Affairs. 2011;30(1): Congressional Budget Office. Offsetting Effects of Prescription Drug Use on Medicare s Spending for Medical Services. Report, November 29, Accessed 7/17/ Amgen Proprietary For Discussion Purposes Only
11 PAYERS AND BIOPHARMA SHARE MUTUAL GOALS Improve the population health of our patients, focusing on those at highest risk Reward interventions that make a real difference, and stop paying for those that don t Reward interventions commensurate with their value Innovative biopharmaceuticals and devices are a part of the solution, but we struggle to understand their value 11 Amgen Proprietary For Discussion Purposes Only
12 AMGEN S VALUE-BASED PROGRAMS AND PARTNERSHIPS TRANSACTIONAL SUPPLIER OF MEDICINES COLLABORATIVE PARTNER WITHIN THE HEALTHCARE SYSTEM Amgen Examples Disease Management Patient Identification Pay for Performance Cost Cap Guarantee Strategic Multi-Disease 12 Amgen Proprietary For Discussion Purposes Only
13 AMGEN AND HARVARD PILGRIM AGREE TO FIRST CARDIOVASCULAR OUTCOMES-BASED REFUND CONTRACT Harvard Pilgrim Refines the Utilization Management Criteria to Help High-Risk Cardiovascular Patients Access Repatha; First-of-its-Kind Contract Will Demonstrate Value to Harvard Pilgrim Plans for Cardiovascular Patients Michael Sherman, Chief Medical Officer, Harvard Pilgrim Health Care Repatha has been shown to have a significant outcome on reducing cardiovascular morbidity for high risk individuals with elevated LDL cholesterol We hope to negotiate more contracts of this type, in which a pharmaceutical company truly has skin in the game going forward. This agreement is the first we have signed in which there is a full refund of all costs related to the medication if the patient experiences a heart attack or stroke while taking it. 1 Joshua Ofman, SVP, Global Value, Access & Pricing, Amgen Given the urgency to reduce LDL cholesterol in patients at high risk of cardiovascular events, we value our relationship with leading health plans like Harvard Pilgrim who have worked with us to refine their utilization management criteria to accelerate access for their high-risk patients. We look forward to partnering with other payers to create similar outcomes-based contracts for Repatha. 2 Sources: 1. Harvard Pilgrim Health Care. (2017). Harvard Pilgrim signs second groundbreaking contract with Amgen for Repatha [Press release]. Retrieved from 2. Amgen. (2017). Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for Repatha (Evolocumab) [Press release]. Retrieved from 13 Amgen Proprietary For Discussion Purposes Only
14 REPATHA OUTCOMES-BASED REBATE (OBR) CONTRACT PLATFORM Patient-focused risk-based contracts Contract requires both medical and pharmacy inputs: Time on therapy Event for the patient Simple value proposition for the plan Offers employer groups and downstream plans access to innovative medicines and potentially manage costs 14 Amgen Proprietary For Discussion Purposes Only
15 ANCHORING ON VALUE PROVIDES A PATH FORWARD Free Pricing What the market will bear based on marketplace and business dynamics Value-Based Pricing Prices anchored to measurement of value (defined broadly) or outcomes Budget-Based Pricing Prices anchored to some measure of short-term affordability Market-based Solutions are Required 15 Amgen Proprietary For Discussion Purposes Only
Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationHealth Policy Commission 1
Health Policy Commission 1 Topics to be covered 1 Spending trends in Massachusetts and the United States Estimated 13% growth in drug spending in MA in 2014 Substantial growth in top drug classes, in addition
More informationIntroduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,
More informationInnovative Approaches to Saving Patients Money on Prescription Drug Costs
Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices
More informationFederal Register /Vol. 72, No. 136 /Tuesday, July 17, 2007 /
Federal Register /Vol. 72, No. 136 /Tuesday, July 17, 2007 / 447.504 Determination of AMP. (a) AMP means, with respect to a covered outpatient drug of a manufacturer (including those sold under an NDA
More informationThe Middle East. 15 Countries*, 5 Time Zones. Population > 333 millions** GDP: $3.13 Trillions*** 58% of world oil reserves
Pharmaco-Economical Overview of Healthcare Omar Rifi, R.Ph., M.B.A. January, 2012-1- The Middle East 15 Countries*, 5 Time Zones Population > 333 millions** GDP: $3.13 Trillions*** 58% of world oil reserves
More informationJuly 13, Dear Secretary Price:
July 13, 2017 The Honorable Thomas E. Price, M.D. Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Secretary Price: At our meeting on May 16,
More informationPrescription Drug Pricing. Page 1
Prescription Drug Pricing Page 1 Prescription Drugs As a Percent of Total National Health Expenditures, 1991-2014 12% 10% 8% 6% 4% 2% 0% 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
More informationIT S WHAT YOU CAN T SEE THAT HURTS YOU IS THE PHARMACEUTICAL INDUSTRY REPLACING EXISTING MEDICATIONS WITH MORE EXPENSIVE MEDICATIONS?
SPECIALTY DRUGS Many plan sponsors have had to make difficult and painful choices about how to spend pharmacy benefit dollars But now payors are once again challenged not just by extremely high costs but
More informationPhRMA Days Press Conference
PhRMA Days Press Conference April 12, 2017 Joaquin Duato Chairman of the Board, PhRMA Roadmap I. Recent Developments in the United States II. Biopharmaceutical Industry s Contribution to Innovation and
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationAccess, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options
Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Ashoke Bhattacharjya, PhD Robert E Campbell Pharmaceutical Seminar Rutgers Business School Feb 15, 2017 1
More informationStrategy resets to patient outcomes. The state of life sciences
Strategy resets to patient outcomes The state of life sciences New innovative products, even at a high cost, can be a great deal for society and the health care system if they cure a chronic disease. Expensive
More informationFrom Volume to Value: Using payer insights to increase sales effectiveness
From Volume to Value: Using payer insights to increase sales effectiveness by Anita Burrell The collective will of the provider community has moved to acquiescence to the payer will controlling costs and
More informationValue-Based Contracting Capabilities Needed for Success
GAME CODE LOWCOST Value-Based ing Capabilities Needed for Success March 9, 2017 Agenda Key Drivers of Value-Based ing (VBC) Major Hurdles to Overcome VBC Adoption Trend VBC Capability Framework 1 Setting
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationPrimer: The Biotechnology Industry Han Zhong l September 2011
Primer: The Biotechnology Industry Han Zhong l September 2011 Introduction The budding biotechnology industry covers a wide range of human health biologic products and technologies that are created by
More informationPut Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits
Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits Presented by Howard Mazzafro, Vice President Innovative Slide 1 of 25 Solutions. Enduring Principles. Innovative Solutions.
More informationThe Future of Generic Pharmaceuticals
The Future of Generic Pharmaceuticals David R. Gaugh, R.Ph. Senior Vice President, Sciences and Regulatory Affairs Generic Pharmaceutical Association A Look Ahead Aging Demographics 1 YEARS OF AGE A Look
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationMARCH Express Scripts 2015 Drug Trend Report Executive Summary
MARCH 2016 Express Scripts 2015 Drug Trend Report Executive Summary Together we brought down out-of-pocket costs for patients and slowed the increase in U.S. drug spend. G oing into 2015, healthcare payers
More informationcomment from interested parties to help shape future policy
This document is scheduled to be published in the Federal Register on 05/16/2018 and available online at https://federalregister.gov/d/2018-10435, and on FDsys.gov Billing Code 4150-03 DEPARTMENT OF HEALTH
More informationDefining the true market
Defining the true market Case study: How real-world data and outcomes improved a major pharmaceutical company s launch strategy Cardinal Health Specialty Solutions Competing in a crowded marketplace A
More informationDrug Development and Delivery for the Next 30 Years: Affordability in an Era of Precision Medicine
Drug Development and Delivery for the Next 30 Years: Affordability in an Era of Precision Medicine By Paul Howard, PhD Director and Senior Fellow, Health Policy Manhattan Institute Chairman Alexander,
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationStatement. For. United States Senate Committee on Finance. June 8, :45 a.m.
Statement of The National Association of Chain Drug Stores For United States Senate Committee on Finance On The President s Fiscal Year 2018 Budget 9:45 a.m. 215 Dirksen Senate Office Building National
More informationTransparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept , 2006 in Washington, DC. Marina Tackitt PBMI
Transparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept. 13-15, 2006 in Washington, DC Marina Tackitt PBMI Session Objectives Summarize Complexity of Drug Benefit Management Define Concept
More informationDrug Spending % of Healthcare Spending DRUG SPENDING % OF HEALTHCARE SPENDING 20% 15% 10% 5% 0% 1995 2000 2005 2010 2015 Japan, 15.0% France, 9.8% US Net, 9.8% UK, 9.7% Germany, 9.0% France Germany Japan
More informationReducing the Cost of Cancer Care: Policy Options from The Leukemia & Lymphoma Society May 2017
Reducing the Cost of Cancer Care: Policy Options from The Leukemia & Lymphoma Society May 2017 The cost of cancer care is rising at an alarming rate, with a growing portion of those costs being shifted
More informationReducing the Cost of Cancer Care: Policy Recommendations from The Leukemia & Lymphoma Society
Reducing the Cost of Cancer Care: Policy Recommendations from The Leukemia & Lymphoma Society The cost of cancer care is rising at an alarming rate, with a growing portion of those costs being shifted
More informationKey learnings from a product launch success story
Insight brief U.S. Market Access: Key learnings from a product launch success story James (Jim) Anderson, Senior Director and Head of Reimbursement, Access & Distribution Solutions Joe Bonaccorso, Vice
More informationThe U.S. Wholesaler Market: Past, Present and Future
The U.S. Wholesaler Market: Past, Present and Future 2012 H. D. Smith National Sales & Management Conference August 8, 2012 John M. Gray President and CEO HDMA The History of HDMA 1876 2012 Exchange Hall,
More informationAntitrust Considerations of Proposals to Limit Rebates
July 15, 2018 I. Introduction Antitrust Considerations of Proposals to Limit Rebates In May 2018, the Department of Health and Human Services (HHS) introduced a policy Blueprint setting forth actions and
More informationIndustry Overview & Strategic Growth Framework
A Pharmacy Innovation Company Industry Overview & Strategic Growth Framework Larry Merlo President & Chief Executive Officer Agenda Rapidly-changing health care environment Uniquely positioned to drive
More informationStatement on Drug Pricing in America: A Prescription for Change. Submitted to the Senate Finance Committee
Statement on Drug Pricing in America: A Prescription for Change Submitted to the Senate Finance Committee January 29, 2019 America s Health Insurance Plans (AHIP) is the national association whose members
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationComparative Effectiveness Research. Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010
Comparative Effectiveness Research Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010 How Evidence Begins No Evidence Beginning of Human Testing FDA Approval
More informationManaging Your Drug Spend. Discussion Topics 8/10/2016. Robert P. Navarro, PharmD Clinical Professor Department of Pharmaceutical Outcomes & Policy
Managing Your Drug Spend Robert P. Navarro, PharmD Clinical Professor Department of Pharmaceutical Outcomes & Policy 2 Discussion Topics Introduction and overview Market conditions, expense centers, and
More informationDoctors Reap Millions for Anemia Drugs
Page 1 of 6 May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world s largest drug companies are paying hundreds of millions of dollars to doctors every
More informationGeneric Pricing and Contract Analytics
Generic Pricing and Contract Analytics May 2017 Tom Evegan Tom.evegan@cumberlandcg.com 732-614-3350 2 Agenda I. Analytics: Keys to Accuracy and Compliance a) Roadmap and Work Steps b) Dashboards and Big
More informationPharmacy Benefit Management (PBM) Overview
Pharmacy Benefit Management (PBM) Overview Agenda Introductions to ARMSRx Team & Services Stephanie Cormier Christine Heutinck The PBM history and role in healthcare CIS key performance indicators (KPIs)
More informationPositioning The PBM For Long-term Success
A Pharmacy Innovation Company Positioning The PBM For Long-term Success Per Lofberg Executive Vice President The Past Three Years Have Set The Stage For Long-term Success Integrated model embraced by market
More informationehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014
ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 Health care is in the middle of a perfect storm Changing demographics Unmet needs
More informationCreating Pre-Patient Relationships through Employer Outreach
Employer Engagement as a Consumer Acquisition Strategy: Creating Pre-Patient Relationships through Employer Outreach Jan Hess Vice President Professional and Administrative Services, St. Luke s Hospital
More informationSpecialty Pharmacy 101
Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current
More informationThe generics environment today
The generics environment today Sergio Napolitano EGA Director Legal Affairs and Trade 2 October 2015, Warsaw C O M PA N I E S N AT I O N A L A S S O C I AT I O N S EGA Membership GE (Hungary) SPMA (Slovenia)
More informationPolicy principles for a competitive healthcare environment
Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationHatch-Waxman: Driving Access, Savings & Innovation
Hatch-Waxman: Driving Access, Savings & Innovation Introduction Thirty years ago, Congress sought to create a balance between access to lower cost generic medicines and incentives to innovate new and better
More informationWhite paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act
White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan
More informationThe 21st Century Cures Act
The 21st Century Cures Act Published: Dec 14, 2016 By: David S. Guzick, M.D., Ph.D.Category: UF Health In recent weeks, the 21st Century Cures Act was passed overwhelmingly by both chambers of the U.S.
More informationReflections on Improving the Interoperability and Use of the Data Dividend
Reflections on Improving the Interoperability and Use of the Data Dividend Betsy L. Humphreys Acting Director National Library of Medicine National Institutes of Health Department of Health and Human Services
More informationClinical Trial Design, Drug Development, and Policy Issues of Importance to Cancer Advocates
Clinical Trial Design, Drug Development, and Policy Issues of Importance to Cancer Advocates Ellen L. Stovall National Coalition for Cancer Survivorship (NCCS) Institute of Medicine Workshop October 5,
More informationOptimize Government Pricing Agreements for Maximum Returns
Optimize Government Pricing Agreements for Maximum Returns 19 th Annual Medicaid and Government Pricing Congress We partner with our clients in the Life Sciences & Healthcare industries to provide direct
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT
ACRUX (ACR) - ASX ANNOUNCEMENT 24 JULY 2017 ACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT Acrux (ASX: ACR) today announced that CEO and Managing Director, Michael Kotsanis presented at the 2017 Bioshares
More informationUnrealized Savings from the Misuse of REMS and Non-REMS Barriers. By Alex Brill
Unrealized Savings from the Misuse of REMS and Non-REMS Barriers By Alex Brill September 2018 EXECUTIVE SUMMARY Risk Evaluation and Mitigation Strategies (REMS) are drug safety programs required by the
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: clinical_trial_services 3/2002 2/2018 2/2019 8/2018 Description of Procedure or Service Clinical trials are
More informationTrends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B,
Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2007-2017 December 2017 THE MORAN COMPANY 1 Trends in Estimated Average Sales Price for Prescription Drugs in Medicare
More informationCoop-etition The pros and cons of collaboration with other standard-setting organizations
Coop-etition The pros and cons of collaboration with other standard-setting organizations Presented by Lynne Gilbertson VP Standards Development National Council for Prescription Drug Programs Open Forum
More informationReal World Evidence and Implications to Value-based Contracting
Real World Evidence and Implications to Value-based Contracting Panel Introductions Mark DeWyngaert, PhD Managing Director Huron Consulting Group Susan Lee Partner, Washington, D.C. Hogan Lovells BJ D
More informationCost-based, Value-based, and Reference-based Pricing for Diagnostics
Cost-based, Value-based, and Reference-based Pricing for Diagnostics James C. Robinson Leonard D. Schaeffer Professor of Health Economics Director, Berkeley Center for Health Technology University of California,
More informationTHE BIOPHARMA DILEMMA:
THE BIOPHARMA DILEMMA: Balancing Innovation and Affordability Amitabh Chandra HARVARD UNIVERSITY Disclosures Panel of Health Advisors, CBO Speaking fees from Biogen, Novo Nordisk, Pfizer, PCMA, Roche Consultant
More informationCommercial Pricing and Contracting 101
Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai
More informationFrequently Asked Questions About Prescription Drug Pricing and Policy
Frequently Asked Questions About Prescription Drug Pricing and Policy Suzanne M. Kirchhoff Analyst in Health Care Financing Judith A. Johnson Specialist in Biomedical Policy Susan Thaul Specialist in Drug
More informationLAUNCH MANAGEMENT. Preparing for a Global Launch. Through Alignment, Communication, Collaboration and Transparency
LAUNCH MANAGEMENT Preparing for a Global Launch Through Alignment, Communication, Collaboration and Transparency Presented by: Lori Peters, QPharma, SVP Commercial Operations Ted Hoffman, Centerline Consulting,
More informationUS Pharmacy Benefit Management Market Report
US Pharmacy Benefit Management Market Report ----------------------------------------- 2014 Executive Summary In the US, Pharmacy Benefit Management (PBM) deals with the management of prescription drug
More informationOUR NEW QUEST. Grounded in Today s Realities While Building for the Future. Steve Rusckowski President and Chief Executive Officer
OUR NEW QUEST Grounded in Today s Realities While Building for the Future Steve Rusckowski President and Chief Executive Officer Safe Harbor Disclosure This presentation may contain forward-looking statements.
More information'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push
Other Publications: Scrip Medtech Insight In Vivo Rose Sheet This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers,
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationAn Economic Analysis of Generic Drug Usage in the U.S.
September 2011 $931 Billion SAVINGS An Economic Analysis of Generic Drug Usage in the U.S. EXECUTIVE SUMMARY As government leaders in Washington and across the country look for ways to cut health care
More informationImportant Facts. Health Care Professionals Should Know About Biosimilars
Important Facts Health Care Professionals Should Know About Biosimilars Biosimilars: Defining Characteristics Biosimilars are highly similar versions of reference biologics, with no clinically meaningful
More informationStrategies for Forecasting and Grossto-Net (GTN) Estimates in a Fluid and Fast-Paced Environment
Strategies for Forecasting and Grossto-Net (GTN) Estimates in a Fluid and Fast-Paced Environment Gaining efficiencies through E2E Process Optimization March 21, 2016 1 Copyright 2016 Deloitte Development
More informationProgram Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
More informationNew Complexities in Pricing Orphan and Ultra-Orphan Drugs
New Complexities in Pricing Orphan and Ultra-Orphan Drugs September 28, 2010 Agenda Orphan drugs and their prices are less rare Changes in ultra-orphan markets Increased competition Big pharma enters When
More informationTHE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead
THE BIOLOGIC DRUG MARKET 2 0 1 7 HOW DO DRUGS AND BIOLOGICS DIFFER? This ebook answers that question, and so much more. OptumRx has summarized the complex and expensive world of biologic drugs for you.
More informationHealth Reform for New Health Reform Reporters Kaiser Family Foundation July 7, 2016
Transcript provided by the (Tip: Click on the binocular icon to search this document) Health Reform for New Health Reform Reporters July 7, 206 The makes every effort to ensure the accuracy of written
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationImplementation of Pharmaceutical Policy Reform. Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank
Implementation of Pharmaceutical Policy Reform Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank Sector issues Critical sector for health outcomes Characterized by market
More informationReal-Life Strategies for Account Managers to Help Grow Market Share
1 CMR Institute 2017. All Rights Reserved. Real-Life Strategies for Account Managers to Help Grow Market Share As an account manager, understanding your customers challenges including their performance
More informationIntroduction. Summary A LOOK AT CFTR MODULATORS FOR CYSTIC FIBROSIS JUNE 2018 TREATMENT OPTIONS CYSTIC FIBROSIS POLICY IMPLICATIONS
JUNE 2018 Introduction CYSTIC FIBROSIS Cystic fibrosis (CF) is a progressive genetic disease that affects many organ systems, though a significant proportion of its morbidity and mortality is associated
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationOn behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic
Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,
More informationTAKE A CLOSER LOOK at Biosimilars
Key Stakeholders Frequently Asked Questions Executive Summary Understanding Biosimilars Potential Benefits of Biosimilars TAKE A CLOSER LOOK at Biosimilars 2018 Trends in Biosimilars Report Message From
More informationPrescription Drugs: What Can States Do?
Strong States, Strong Nation Prescription Drugs: What Can States Do? PROFESSIONAL LEGISLATIVE STAFF SEMINAR October 10-12, 2018 NCSL Health Program . 2 . NCSL Reports, Tracking, TAs, Meetings and more
More informationDon Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201
October 17, 2018 Don Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201 Re: Request for Information Regarding the
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationMORE OF WHAT MATTERS. Update: UnitedHealthcare Pharmacy Benefit Transition. February 26, 2013
MORE OF WHAT MATTERS Update: UnitedHealthcare Pharmacy Benefit Transition February 26, 2013 Success matters It s time for a better plan. At UnitedHealthcare, we give you more of what matters: MORE ACCOUNTABILITY
More informationThe Pharma/Payer Relationship Strategies for the Next Two Years
Health & Life Sciences The Pharma/Payer Relationship Strategies for the Next Two Years by Mark Mozeson Nipon Das, M.D. The power to determine what pharmaceutical products are bought and at what price has
More informationDerm Drugs: The Price is Too Darn High!
Derm Drugs: The Price is Too Darn High! By Jacob Levitt, MD, FAAD Vice Chairman, Program Director, and Associate Professor The Mount Sinai Medical Center Department of Dermatology New York, NY 1 Disclosures
More informationNandan Kenkeremath, JD. Leading Edge Policy & Strategy, LLC
Nandan Kenkeremath, JD Leading Edge Policy & Strategy, LLC 1 Definitions, Framework, Relationships 2007 Joint Principles on Patient Centered Medical Homes Payment Task Force Report Leading Edge Policy
More informationBLUNDERS. in Contracting With a PBM
5 COMMON BLUNDERS in Contracting With a PBM by Gannon Murphy, Ph.D., and Seth A. Friedman The language in contracts with pharmacy benefit managers (PBMs) can be quite complex. Avoiding these five common
More information7/20/2016. Disclaimer
Disclaimer Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the
More information2016 CSR Report Summary
2016 CSR Report Summary Our goal is always to address new issues proactively and increase transparency in the process. CVS Health At-a-Glance Our Prescription for a Better World At CVS Health, everything
More informationCURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE
CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE Consumer Advocare Network s submission to WHO's Second Public Hearing on Public Health Innovation and Intellectual Property The Consumer Advocare
More informationPerspective on the Price of Innovative Prescription Medicines
Perspective on the Price of Innovative Prescription Medicines Over the past four decades, the return on investment to society from the development of innovative medicines has been substantial. Biomedical
More informationCritical Incentive Strategies for Accelerating R&D to Fight Against AMR
Critical Incentive Strategies for Accelerating R&D to Fight Against AMR Greg Daniel, PhD, MPH Deputy Director, Duke-Margolis Center for Health Policy Clinical Professor, Fuqua School of Business Adjunct
More information